TY - JOUR
T1 - Effect of omega-3 fatty acids on heart rate variability in depressed patients With Coronary Heart Disease
AU - Carney, Robert M.
AU - Freedland, Kenneth E.
AU - Stein, Phyllis K.
AU - Steinmeyer, Brian C.
AU - Harris, William S.
AU - Rubin, Eugene H.
AU - Krone, Ronald J.
AU - Rich, Michael W.
PY - 2010/10
Y1 - 2010/10
N2 - Objective: To determine whether omega-3 fatty acid (FA) increases the natural log of very low frequency (lnVLF) power, an index of heart rate variability (HRV), and reduces 24-hour heart rate (HR) in depressed patients with coronary heart disease (CHD). Low intake of omega-3 FAs is associated with depression and with low HRV, and all three are associated with an increased risk of death in patients with CHD. Methods: Thirty-six depressed patients with CHD randomized to receive 50 mg of sertraline and 2 g of omega-3/day, and 36 randomized to sertraline and a placebo, had 24-hour HRV measured at baseline and after 10 weeks of treatment. Results: There was a significant treatment × time interaction for covariate adjusted lnVLF (p = .009), for mean 24-hour HR (p = .03), and for 1-minute resting HR (p = .02). The interaction was not significant for three other measures of HRV. LnVLF did not change over time in the omega-3 arm but decreased in the placebo arm (p = .002), suggesting that omega-3 may have prevented or slowed deterioration in cardiac autonomic function. Conclusions: The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3. Whether a longer course of treatment or a higher dose of omega-3 would further decrease HR, improve other indices of HRV, or reduce mortality in depressed CHD patients should be investigated.
AB - Objective: To determine whether omega-3 fatty acid (FA) increases the natural log of very low frequency (lnVLF) power, an index of heart rate variability (HRV), and reduces 24-hour heart rate (HR) in depressed patients with coronary heart disease (CHD). Low intake of omega-3 FAs is associated with depression and with low HRV, and all three are associated with an increased risk of death in patients with CHD. Methods: Thirty-six depressed patients with CHD randomized to receive 50 mg of sertraline and 2 g of omega-3/day, and 36 randomized to sertraline and a placebo, had 24-hour HRV measured at baseline and after 10 weeks of treatment. Results: There was a significant treatment × time interaction for covariate adjusted lnVLF (p = .009), for mean 24-hour HR (p = .03), and for 1-minute resting HR (p = .02). The interaction was not significant for three other measures of HRV. LnVLF did not change over time in the omega-3 arm but decreased in the placebo arm (p = .002), suggesting that omega-3 may have prevented or slowed deterioration in cardiac autonomic function. Conclusions: The effects of omega-3 FAs on lnVLF and HR, although modest, were detected after only 10 weeks of treatment with 2 g per day of omega-3. Whether a longer course of treatment or a higher dose of omega-3 would further decrease HR, improve other indices of HRV, or reduce mortality in depressed CHD patients should be investigated.
KW - Depression
KW - Heart rate variability
KW - Omega-3
UR - http://www.scopus.com/inward/record.url?scp=78049510008&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78049510008&partnerID=8YFLogxK
U2 - 10.1097/PSY.0b013e3181eff148
DO - 10.1097/PSY.0b013e3181eff148
M3 - Article
C2 - 20716712
AN - SCOPUS:78049510008
SN - 0033-3174
VL - 72
SP - 748
EP - 754
JO - Psychosomatic Medicine
JF - Psychosomatic Medicine
IS - 8
ER -